克立硼罗 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "克立硼罗" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
1,523rd place
3,448th place
5th place
12th place
274th place
320th place
low place
7,863rd place
doi.org
- A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology (PDF). Dermatology Online Journal. May 2014, 20 (5): 22608 [2022-03-19]. PMID 24852768. doi:10.5070/D3205022608. （原始内容 (PDF)存档于2017-10-05）.
- Exploration of Solid Forms of Crisaborole: Crystal Engineering Identifies Polymorphism in Commercial Sources and Facilitates Cocrystal Formation. Crystal Growth & Design. 2018, 18 (8): 4416–4419. ISSN 1528-7483. doi:10.1021/acs.cgd.8b00375.
escholarship.org
- A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology (PDF). Dermatology Online Journal. May 2014, 20 (5): 22608 [2022-03-19]. PMID 24852768. doi:10.5070/D3205022608. （原始内容 (PDF)存档于2017-10-05）.
europa.eu
ema.europa.eu
- Staquis EPAR. European Medicines Agency (EMA). 29 January 2020 [28 April 2020]. （原始内容存档于2021-11-02）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
fda.gov
fda.gov
- FDA Approves Eucrisa for Eczema (新闻稿). U.S. Food and Drug Administration (FDA). 14 December 2016 [2022-03-19]. （原始内容存档于2019-04-23）.
本文含有此來源中屬於公有领域的内容。
accessdata.fda.gov
- Eucrisa (crisaborole) Ointment. U.S. Food and Drug Administration (FDA). 23 January 2017 [28 April 2020]. （原始内容存档于2020-08-08）.
hres.ca
hpr-rps.hres.ca
- Eucrisa Regulatory Decision Summary. Health Canada. 2014-10-23 [2019-09-14]. （原始内容存档于2019-09-14）.
- Eucrisa Regulatory Decision Summary. Health Canada. 2014-10-23 [2019-09-14]. （原始内容存档于2019-09-14）.
pdf.hres.ca
- PRODUCT MONOGRAPH (PDF). Government of Canada. 2018-06-07 [2019-04-07]. （原始内容 (PDF)存档于2019-04-07）.
nih.gov
ncbi.nlm.nih.gov
- A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology (PDF). Dermatology Online Journal. May 2014, 20 (5): 22608 [2022-03-19]. PMID 24852768. doi:10.5070/D3205022608. （原始内容 (PDF)存档于2017-10-05）.
- AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Current Opinion in Investigational Drugs. November 2009, 10 (11): 1236–42. PMID 19876791.
dailymed.nlm.nih.gov
- Eucrisa- crisaborole ointment. DailyMed. 21 April 2020 [28 April 2020]. （原始内容存档于2021-03-23）.
pfizer.com
- Pfizer to Acquire Anacor. Pfizer (新闻稿). 16 May 2016 [28 April 2020]. （原始内容存档于2020-04-28）.
q4cdn.com
s21.q4cdn.com
- Pfizer Financial Report (PDF). Pfizer. [9 April 2020]. （原始内容 (PDF)存档于2020-02-02）.
web.archive.org
- FDA Approves Eucrisa for Eczema (新闻稿). U.S. Food and Drug Administration (FDA). 14 December 2016 [2022-03-19]. （原始内容存档于2019-04-23）. 本文含有此來源中屬於公有领域的内容。
- Eucrisa- crisaborole ointment. DailyMed. 21 April 2020 [28 April 2020]. （原始内容存档于2021-03-23）.
- Staquis EPAR. European Medicines Agency (EMA). 29 January 2020 [28 April 2020]. （原始内容存档于2021-11-02）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- PRODUCT MONOGRAPH (PDF). Government of Canada. 2018-06-07 [2019-04-07]. （原始内容 (PDF)存档于2019-04-07）.
- A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology (PDF). Dermatology Online Journal. May 2014, 20 (5): 22608 [2022-03-19]. PMID 24852768. doi:10.5070/D3205022608. （原始内容 (PDF)存档于2017-10-05）.
- WHO Drug Information, Vol. 29, No. 3, 2015. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74 (PDF). World Health Information. [26 April 2016]. （原始内容 (PDF)存档于2016-05-18）.
- Crisaborole. AdisInsight. [24 July 2017]. （原始内容存档于2018-07-20）.
- Pfizer to Acquire Anacor. Pfizer (新闻稿). 16 May 2016 [28 April 2020]. （原始内容存档于2020-04-28）.
- Pfizer Financial Report (PDF). Pfizer. [9 April 2020]. （原始内容 (PDF)存档于2020-02-02）.
- Eucrisa (crisaborole) Ointment. U.S. Food and Drug Administration (FDA). 23 January 2017 [28 April 2020]. （原始内容存档于2020-08-08）.
- Eucrisa Regulatory Decision Summary. Health Canada. 2014-10-23 [2019-09-14]. （原始内容存档于2019-09-14）.
- Eucrisa Regulatory Decision Summary. Health Canada. 2014-10-23 [2019-09-14]. （原始内容存档于2019-09-14）.
who.int
- WHO Drug Information, Vol. 29, No. 3, 2015. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74 (PDF). World Health Information. [26 April 2016]. （原始内容 (PDF)存档于2016-05-18）.
worldcat.org
- Exploration of Solid Forms of Crisaborole: Crystal Engineering Identifies Polymorphism in Commercial Sources and Facilitates Cocrystal Formation. Crystal Growth & Design. 2018, 18 (8): 4416–4419. ISSN 1528-7483. doi:10.1021/acs.cgd.8b00375.